Azelaic Acid vs Hydroquinone: Which Fades Spots Better?

Azelaic acid vs hydroquinone has no universal winner. For melasma, 20% azelaic acid performed about as well as 4% hydroquinone in the largest direct trial. A pooled analysis found a small score advantage for azelaic acid, but other outcomes did not separate them. Azelaic acid often fits a non-hydroquinone route, especially when acne is also present. Hydroquinone fits clinician-diagnosed melasma when a prescriber wants a short, monitored treatment. Pregnancy changes the decision.

Azelaic acid vs hydroquinone: the practical comparison

What the evidence and current labels let you compare

Decision point	Azelaic acid	Hydroquinone
Form tested head to head	20% cream	Mostly 4% cream; one major trial used 2% cream
Direct result	The largest 24-week trial found no statistically significant difference between 20% azelaic acid and 4% hydroquinone. A six-trial meta-analysis found a small MASI-score advantage for azelaic acid, but no difference on several other outcomes.
Evidence window	8–24 weeks in direct trials	8–24 weeks in direct trials
Common drawbacks	Stinging, burning, itching and dryness; isolated hypopigmentation reports	Stinging, redness and dermatitis; a distinct risk of blue-black ochronosis
United States access	20% cream is prescription-only and approved for acne, not melasma; 10% cosmetics do not match the trial strength	No legal over-the-counter hydroquinone; the only FDA-approved hydroquinone drug is a prescription triple-combination treatment
United Kingdom access	20% Skinoren is prescription-only and licensed for acne, not melasma	The British Association of Dermatologists says it can only be prescribed by doctors
Pregnancy	Labels say controlled human data are lacking; US wording says only if clearly needed, while the UK label tells prescribers to use caution	UK guidance advises avoiding it; the approved US hydroquinone combination contains tretinoin and carries an embryo-fetal warning

What did the head-to-head trials find?

There are direct trials. This is a review of published evidence, not a test of our own.

Albzea and colleagues pooled six randomized trials with 673 people in a 2023 Cureus review. Azelaic acid produced a 1.23-point greater mean reduction on the Melasma Area and Severity Index. The 95% confidence interval ran from 0.40 to 2.05 MASI points in its favour. Yet the groups did not differ on objective response, pigment reduction or reported adverse events.

The review also found limits. Two trials had low risk of bias, two raised some concerns and two had high risk. Most participants were middle-aged women with melasma. Follow-up was short, and the trials used different protocols. The MASI result is a useful signal, not proof that azelaic acid works better for every person or every dark spot.

The biggest study gives the clearest reality check. Baliña and Graupe compared 20% azelaic acid with 4% hydroquinone in 329 women for 24 weeks. Everyone also used broad-spectrum sunscreen. Azelaic acid produced a good or excellent result in 65% of its group. The researchers found no statistically significant treatment difference in the total rating, patch size or pigment intensity.

An older 24-week trial by Verallo-Rowell and colleagues looks more dramatic. Among 155 Indo-Malay-Hispanic patients, 73% had a good or excellent response with 20% azelaic acid. That figure was 19% with hydroquinone. But the hydroquinone strength was 2%, not 4%. It cannot show that azelaic acid beats the prescription strength used in the larger trial.

Hydroquinone still has a central place in melasma care. A 2026 international consensus called supervised hydroquinone-based triple-combination cream the standard medical option and listed azelaic acid as an alternative. That statement concerns a three-drug prescription, not hydroquinone alone. It does not contradict the close monotherapy comparison above.

How long should fading take?

The direct studies measured outcomes after 8–24 weeks. The largest ran for 24 weeks. They do not support a promise that either option clears pigment within days. They also do not prove that hydroquinone works faster.

Use the planned review date from your prescriber rather than changing a prescription yourself. For a home record, take one baseline photo and repeat it every four weeks. Keep the same camera, distance, room, exposure and time of day. This is an editorial tracking method, not a validated clinical test. Depth and cause change the pace.

Judge the patch, not your whole face tone. A brighter window or automatic phone exposure can create an apparent result that no treatment caused.

Melasma evidence does not cover every dark spot

The direct comparison is mainly about melasma. Post-inflammatory marks after acne, discrete sun spots and freckles are different problems. A ranking from melasma trials cannot be copied across them.

If a mark followed a pimple or irritation, start with the cause and the guidance on post-inflammatory hyperpigmentation in darker skin. If you are unsure what the patch is, compare the patterns in our freckles, sun spots and melasma guide. A changing, bleeding or unusual spot needs a clinician's diagnosis before any fading treatment.

Strength matters too. Most head-to-head evidence used 20% azelaic acid. It does not establish that a 10% cosmetic serum equals 20% cream. The azelaic acid strength comparison separates product access from what each concentration has actually tested.

Side effects and prescription status change the choice

Both options can irritate. The current US label for 20% azelaic acid lists itching, burning, stinging and tingling in about 1%–5% of patients in its acne trials. It also records isolated hypopigmentation reports and asks clinicians to monitor darker complexions. Those label data come from acne use, so they do not measure melasma benefit.

Hydroquinone can cause redness, stinging or contact dermatitis. Its distinctive danger is exogenous ochronosis, a gradual blue-black darkening that may be permanent. The FDA has received reports of this reaction from skin-lightening products. Swelling, severe irritation or blue-black darkening needs prompt medical review.

Access was checked on 8 November 2026. The FDA says hydroquinone cannot be legally sold over the counter in the United States. Its only approved hydroquinone-containing drug is prescription Tri-Luma for short-term treatment of moderate-to-severe facial melasma. US 20% azelaic acid cream is also prescription-only, and its approval is for acne. In the UK, 20% Skinoren is a prescription acne medicine. The British Association of Dermatologists says hydroquinone can only be prescribed by doctors. Our explanation of why hydroquinone is restricted covers that regulatory distinction.

Pregnancy is not the time to choose between them alone. The British Association of Dermatologists advises avoiding hydroquinone during pregnancy. The approved US Tri-Luma label carries an embryo-fetal warning because that combination contains tretinoin. It does not establish the safety of hydroquinone used alone. The US 20% azelaic acid label says adequate controlled human studies do not exist. It limits use to cases a clinician considers clearly needed. The UK azelaic acid label likewise tells prescribers to use caution.

How do you stop the pigment returning?

Melasma often returns after treatment stops. The active is only one part of the result. Light exposure and irritation can keep pigment production active.

Castanedo-Cazares and colleagues tested this in 68 people with melasma. Everyone received 4% hydroquinone, while the sunscreen differed. After eight weeks, 61 people completed the trial. The sunscreen that also covered visible light produced 15% greater MASI improvement than the UV-only sunscreen. Colour measurements improved 28% more, while measured melanin improved 4% more. This small study does not compare the two actives. It shows that photoprotection can change the apparent treatment result.

1. Confirm whether the pigment is melasma, a post-acne mark or another lesion.
2. Follow the prescriber's plan without adding extra acids or changing a prescription yourself.
3. Use broad-spectrum SPF 30 or higher; for melasma, consider a tinted option with iron oxides for visible-light coverage.
4. Track one comparable photo every four weeks and review persistent pigment with the clinician.

How to decide, and when a dermatologist should decide

Azelaic acid is the cleaner discussion when you want a non-hydroquinone option, acne is also part of the problem, or hydroquinone is unsuitable. Hydroquinone is a clinician-led choice for confirmed, persistent melasma when a short monitored treatment makes sense. The evidence does not justify calling either monotherapy the universal winner.

A dermatologist should make the call when the diagnosis is uncertain, the pigment is changing, pregnancy or breastfeeding applies, or a prescription is involved. Get reviewed if treatment causes marked irritation, swelling, colour loss or blue-black darkening. If a properly followed plan has not helped by its review date, ask the clinician to recheck the diagnosis and triggers. Do not increase the strength yourself.